Business
Allstate is one of the largest publicly held personal lines insurers in the United States, with property-liability insurance, protection services, and health and benefits operations.
Allstate revenue rose 5.6% and net income more than doubled to $10.28B, with buybacks rising to $1.23B.
The read at a glance✓ Audited against SEC data
- Business mix — Personal lines insurance and protection servicesNote
- Revenue — Revenue rose 5.6% to $67.69BOK
- Profitability — Net income rose to $10.28BOK
- Cash — Free cash flow was $9.88BOK
- Capital returns — $2.27B returned via buybacks and dividendsOK
- Insiders — 0 buys / 22 sellsWatch
- Accounting — No forensic screen in bundleNote
Where the revenue comes from
Fiscal 2025, as ALLSTATE CORP reports it. History and quarterly detail are in the app.
- Property Liability$59.7B
- Protection Services$3.5B
- Allstate Health and Benefits$676.0M
- Corporate$308.0M
Leadership changes
From ALLSTATE CORP's own filings, the day they're filed.
- Richard T. Hume · member of the board of directors · departureeff. 2025-11-21
- Eric K. Ferren · President · appointmenteff. 2024-05-20
- John C. Pintozzi · President · appointmenteff. 2024-05-20
Latest filings
- 8-K · Company announcement2026-08-20
- 8-K · Company announcement2026-08-05
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-07-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ALLSTATE CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.